Research prototype, not medical advice.

In the CANTOS phase III trial, canakinumab (anti-IL-1beta) cut cardiovascular events by 15% in post-heart-attack patients with high CRP, but increased fatal infections.

Confidence
Established
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Chronic inflammationCanakinumab (anti-IL-1β)Interleukin-1 betaCardiovascular disease

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker et al. · New England Journal of Medicine 2017
— Verified

Related claims